CC-5013 (Lenalidomide) is a potent immunomodulatory CRBN E3 ligase modulator. It affects NF-κB, ERK, and MYC signaling pathways, by inducing CRBN-dependent ubiquitination and proteasomal degradation of IKZF1/3 and CK1α, inhibiting tumor proliferation and promoting NK/T cell-mediated cytotoxicity.
CC-5013 (Lenalidomide) IC50 for Cell-based and Cell-free Assays
Comprehensive IC50 Values for CC-5013 (Lenalidomide) Across Cell-free Enzyme Inhibitory Profiles and Cell-based Functional Assays.